S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65

Aroa Biosurgery Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive ARX News and Ratings via Email

Sign-up to receive the latest news and ratings for Aroa Biosurgery and its competitors with MarketBeat's FREE daily newsletter.

About Aroa Biosurgery

Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and selling of medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobia for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. The company was incorporated in 2007 and is headquartered in Auckland, New Zealand.


No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
$22.34 million
Book Value
A$0.19 per share





Next Earnings Date
Not Optionable


Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Aroa Biosurgery (ASX:ARX) Frequently Asked Questions

What stocks does MarketBeat like better than Aroa Biosurgery?

Wall Street analysts have given Aroa Biosurgery a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aroa Biosurgery wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aroa Biosurgery's next earnings date?

Aroa Biosurgery is scheduled to release its next quarterly earnings announcement on Wednesday, November 24th 2021.
View our earnings forecast for Aroa Biosurgery

Who are Aroa Biosurgery's key executives?

Aroa Biosurgery's management team includes the following people:
  • Dr. Brian Ward, Founder, CEO, MD & Exec. Director
  • Mr. James Agnew, CFO & Company Sec.
  • Ms. Simone Von Fircks, VP of Operations
  • Dr. Barnaby C.H. May, VP of Technology
  • Ms. Tracy Weimar BA, MBA, Company Sec.

What other stocks do shareholders of Aroa Biosurgery own?

What is Aroa Biosurgery's stock symbol?

Aroa Biosurgery trades on the ASX under the ticker symbol "ARX."

How much money does Aroa Biosurgery make?

Aroa Biosurgery has a market capitalization of $0.00 and generates $22.34 million in revenue each year.

How many employees does Aroa Biosurgery have?

Aroa Biosurgery employs 147,000 workers across the globe.

What is Aroa Biosurgery's official website?

The official website for Aroa Biosurgery is www.arcexploration.com.au.

How can I contact Aroa Biosurgery?

The company can be reached via phone at 61 8 6117 0452.

This page was last updated on 10/19/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.